All In Biotech

Drug Trial Radar · NCT07406347

A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age

A Phase 1, Observer-blind, Randomized, Active Controlled Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jan 25, 2027

Primary completion

Oct 18, 2028

Study completion Oct 18, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 42 days, up to 90 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate safety and reactogenicity of the investigational pneumococcal vaccine (called Pn-MAPS30plus). PCV20 will be used as a comparator for this study

Conditions

  • Pneumonia, Bacterial

Interventions

  • Pn-MAPS30plusBiological

    Pn-MAPS30plus vaccine will be administered intramuscularly.

  • PCV20Combination product

    PCV20 vaccine will be administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with solicited administration site adverse events (AEs)Time frame: Day 1 to Day 7
  2. Number of participants with solicited systemic adverse events (AEs)Time frame: Day 1 to Day 7
  3. Number of participants with unsolicited AEsTime frame: Day 1 to Day 30
  4. Number of Participants with Serious AEs (SAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to WithdrawalTime frame: Day 1 up to trial end (Month 16)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.